Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490018 | 0.78 | CIT (0.38) | EGFRJAK3 | |
| SCHEMBL21620553 | 0.76 | TRPA1 (0.38) | EGFRJAK3JAK1KITTRPA1 | |
| SCHEMBL4569236 | 0.68 | FFAR2 (0.33) | JAK3FFAR2 | |
| SCHEMBL10105611 | 0.67 | FFAR2 (0.32) | FFAR2 | |
| SCHEMBL12120591 | 0.67 | JAK3 (0.59) | JAK3JAK1TRPA1 | |
| SCHEMBL2611044 | 0.67 | RET (0.55) | — | |
| SCHEMBL20857341 | 0.67 | IRAK4 (0.39) | EGFRKITTRPA1 | |
| SCHEMBL29975653 | 0.67 | JAK3 (0.59) | JAK3JAK1TRPA1 | |
| SCHEMBL18868081 | 0.66 | IRAK4 (0.41) | TRPA1 | |
| SCHEMBL20609574 | 0.64 | USP10 (0.45) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | EGFR 144/4885JAK3 1720/4885JAK1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.